| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $54.8M | -51.6% |
| SG&A Expense | $48.9M | +2.0% |
| Operating Income | -$103.7M | +35.7% |
| Net Income | -$98.8M | +37.1% |
| EPS (Basic) | -$3.28 | +38.1% |
| EPS (Diluted) | -$3.28 | +38.1% |
| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.1M | -24.2% |
| Short-term Investments | $92.2M | -35.5% |
| Accounts Receivable | $512K | +0.0% |
| Current Assets | $97.5M | -36.2% |
| Total Assets | $97.6M | -36.2% |
| Current Liabilities | $12.2M | -2.2% |
| Total Liabilities | $12.2M | -2.2% |
| Line Item | 2023-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$51.7M | +50.2% |
| Investing Cash Flow | $50.5M | +155.7% |
| Financing Cash Flow | -$98K | -100.2% |
| Stockholders' Equity |
| $85.4M |
| -39.2% |